Indications of plasma exchanges in combination with intravenous immunoglobulins or therapeutic monoclonal antibodies. How to combine them?

[1]  L. Kılıç,et al.  Therapeutic plasma exchange for refractory SLE: A comparison of outcomes between different sub-phenotypes. , 2017, European journal of rheumatology.

[2]  P. Coppo,et al.  Thrombotic thrombocytopenic purpura. , 2017, Blood.

[3]  J. Hogan,et al.  Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[4]  N. Dunbar,et al.  临床实践中治疗性单采术应用指南——基于美国血浆置换学会编写委员会的循证策略：第七版 , 2016 .

[5]  N. Dunbar,et al.  Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue , 2016, Journal of clinical apheresis.

[6]  P. Srivaths,et al.  The Pharmacokinetics of Intradialytic Administration of Eculizumab in an Infant. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  S. Watkins,et al.  Guideline on the clinical use of apheresis procedures for the treatment of patients and collection of cellular therapy products , 2015, Transfusion medicine.

[8]  L. Rostaing,et al.  Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. , 2013, British journal of clinical pharmacology.

[9]  G. Remuzzi,et al.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. , 2013, The New England journal of medicine.

[10]  Mark E. Williams,et al.  Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue , 2013, Journal of clinical apheresis.

[11]  J. Winters.  Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. , 2012, Hematology. American Society of Hematology. Education Program.

[12]  S. Piepers,et al.  Immune Pathogenesis and Treatment of Multifocal Motor Neuropathy , 2012, Journal of Clinical Immunology.

[13]  D. Cornblath,et al.  Evidence-based guideline update: Plasmapheresis in neurologic disorders , 2011, Neurology.

[14]  M. Scully,et al.  Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura , 2010, Journal of thrombosis and haemostasis : JTH.

[15]  W. Hop,et al.  Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain‐Barré syndrome , 2009, Annals of neurology.

[16]  R. Ransohoff,et al.  Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function , 2009, Neurology.

[17]  P. Swerdlow,et al.  Drug Removal by Plasmapheresis: An Evidence‐Based Review , 2007, Pharmacotherapy.

[18]  D. J. Unsworth,et al.  Therapeutic apheresis--plasmapheresis. , 2006, Clinical medicine.

[19]  M. H. Ensom,et al.  Pharmacokinetics of Intravenous Immunoglobulin: A Systematic Review , 2006, Pharmacotherapy.

[20]  A. Berg,et al.  Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. , 2006, American journal of clinical pathology.

[21]  L. Arcaini,et al.  Pharmacokinetic Behavior of Rituximab: A Study of Different Schedules of Administration for Heterogeneous Clinical Settings , 2005, Therapeutic drug monitoring.

[22]  J. Fortenberry,et al.  Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. , 2005, Kidney international.

[23]  M. Taniwaki,et al.  Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  R. Sarode,et al.  Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature , 2004, British journal of haematology.

[25]  Michael E. Williams,et al.  Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia1 , 2004, The Journal of Immunology.

[26]  A. Garg,et al.  Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. , 2003, JAMA.

[27]  A. Cnaan,et al.  Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. , 2003, JAMA.

[28]  L. Mccarthy.  The Challenge of Evidence‐based Medicine for Apheresis , 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[29]  K. Calis,et al.  Extracorporeal removal of antimicrobials during plasmapheresis , 2003, Journal of clinical apheresis.

[30]  M. Dalakas.  Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies , 2002, Neurology.

[31]  B. Hartmann,et al.  Therapeutic plasma exchange in the intensive care setting. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[32]  H. Meier‐Kriesche,et al.  Removal of basiliximab by plasmapheresis. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  P. Kale-Pradhan,et al.  A Review of the Effects of Plasmapheresis on Drug Clearance , 1997, Pharmacotherapy.

[34]  M. Dalakas.  Intravenous Immune Globulin Therapy for Neurologic Diseases , 1997, Annals of Internal Medicine.

[35]  R. P. Kleyweg,et al.  Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[36]  G. Chan,et al.  Effect of Plasmapheresis on Cyclosporine Pharmacokinetics , 1991, DICP : the annals of pharmacotherapy.

[37]  R. Ponikvar,et al.  Effect of plasmapheresis on blood and plasma cyclosporin levels. , 1990, Progress in clinical and biological research.

[38]  S. Urbaniak,et al.  Coagulation Abnormalities following Intensive Plasma Exchange on the Cell Separator , 1981, British journal of haematology.

[39]  E. Berkman,et al.  Partial plasma exchange using albumin replacement: removal and recovery of normal plasma constituents. , 1980, Blood.

[40]  W. Engel,et al.  The hemostatic imbalance of plasma-exchange transfusion. , 1979, Blood.